Evidence map›Paper›PMID 40492381›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

A Tailored Artificial Biocatalyst for Bacterial Endophthalmitis Therapy via Enhanced Ferroptosis-Like Death.

Caixia Sun, Yingying Jiang, Shibo Zhang, Zhipeng Ding, Lijun Pu, Xinmei Liu, Jun Yang, Xiangkai Zhuge, Jianjun Dai, Yanmin Ju

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Caixia SunCollege of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Yingying JiangDepartment of Ophthalmology, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, 215600, China.
Shibo ZhangCollege of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Zhipeng DingCollege of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Lijun PuDepartment of Ophthalmology, The Affiliated Zhangjiagang Hospital of Soochow University, Suzhou, 215600, China.
Xinmei LiuNanjing Institute for Food and Drug Control, Nanjing, 210038, China.
Jun YangNanjing Institute for Food and Drug Control, Nanjing, 210038, China.
Xiangkai ZhugeSchool of Public Health, Nantong University, Nantong, 226019, China.
Jianjun DaiCollege of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.
Yanmin JuCollege of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.ORCID https://orcid.org/0000-0002-5158-3846

Funding

Fundamental Research Funds for the Central Universities 2632024TD02Fundamental Research Funds for the Central Universities 2632024ZD07National Natural Science Foundation of China 32172855Open Project of Jiangsu Provincial Science and Technology Resources (Clinical Resources) Coordination Service Platform TC2023B001Science and Technology Project of State Administration for Market Regulation 2022MK158
6 · The paper itself

Abstract

Bacterial endophthalmitis is an ophthalmological emergency that can lead to permanent blindness, and high-efficiency therapeutic strategies that can completely eradicate pathogens within a short timeframe are needed. However, intrinsic limitations of this disease, such as low administration frequency and dosage, render most currently available nano-antibacterial strategies inapplicable. To address this challenge, a bio-targeted catalytic strategy that is based on a bacteria-specific artificial biocatalyst (MoS

Indexed as

Anti-Bacterial AgentsEndophthalmitisFerroptosisStaphylococcal InfectionsAnimalsHumansMiceReactive Oxygen SpeciesStaphylococcus aureusAnti-Bacterial AgentsReactive Oxygen Speciesartificial biocatalystsbacterial endophthalmitisenhanced ferroptosis‐like deathpeptidoglycan targeting

Identifiers

PMID40492381
PMCPMC12412499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.